(Q58369319)

English

Thioredoxin reductase, an emerging target for anticancer metallodrugs. Enzyme inhibition by cytotoxic gold(iii) compounds studied with combined mass spectrometry and biochemical assays

No description defined

In more languages

Statements

scholarly article

0 references

Thioredoxin reductase, an emerging target for anticancer metallodrugs. Enzyme inhibition by cytotoxic gold(iii) compounds studied with combined mass spectrometry and biochemical assays (English)

0 references

0 references

Guido Mastrobuoni

object named as

Guido Mastrobuoni

2

0 references

Chiara Gabbiani

object named as

Chiara Gabbiani

1

0 references

Giuseppe Pieraccini

object named as

Giuseppe Pieraccini

8

0 references

object named as

Angela Casini

10

0 references

object named as

Luigi Messori

9

0 references

Maria Pia Rigobello

5

object named as

Maria Pia Rigobello

0 references

Alberto Bindoli

6

object named as

Alberto Bindoli

0 references

Francesca Sorrentino

3

object named as

Francesca Sorrentino

0 references

author name string

Barbara Dani

4

0 references

Maria Agostina Cinellu

7

0 references

publication date

2011

0 references

0 references

2

0 references

1

0 references

50-54

0 references

Trans-platinum complexes in cancer therapy

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents.

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Bioorganometallic chemistry--from teaching paradigms to medicinal applications

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Metal-based antitumour drugs in the post genomic era.

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Cysteine proteases as targets for metal-based drugs

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Physiological functions of thioredoxin and thioredoxin reductase

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Cloning and sequencing of a human thioredoxin reductase

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Human mitochondrial thioredoxin reductase cDNA cloning, expression and genomic organization

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Thioredoxin reductase as a pathophysiological factor and drug target

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Terpyridine-platinum(II) complexes are effective inhibitors of mammalian topoisomerases and human thioredoxin reductase 1

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

The structure of human thioredoxin reductase 1 provides insights into C-terminal rearrangements during catalysis

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Inhibition of the human thioredoxin system. A molecular mechanism of mercury toxicity.

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Synthesis of 5-nitro-2-furancarbohydrazides and their cis-diamminedichloroplatinum complexes as bitopic and irreversible human thioredoxin reductase inhibitors

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamato complexes.

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Anti-cancer potential of gold complexes

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Anticancer therapeutics that target selenoenzymes: synthesis, characterization, in vitro cytotoxicity, and thioredoxin reductase inhibition of a series of gold(I) complexes containing hydrophilic phosphine ligands

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Solution chemistry and cytotoxic properties of novel organogold(III) compounds

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Mechanistic studies on a novel, highly potent gold-phosphole inhibitor of human glutathione reductase

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Reactions of gold(III) complexes with serum albumin

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Activity of Rat Cytosolic Thioredoxin Reductase Is Strongly Decreased bytrans-[Bis(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: First Report of Relevant Thioredoxin Reductase Inhibition for a Ruthenium Compound

1 reference

https://api.crossref.org/works/10.1039%2FC0MD00181C

21 January 2018

Identifiers

10.1039/C0MD00181C

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58369319&oldid=1768648654"